No Data
Yantai Zhenghai Biotechnology Co., Ltd.'s (SZSE:300653) Market Cap up CN¥547m Last Week, Benefiting Both Individual Investors Who Own 43% as Well as Insiders
Yantai Zhenghai Bio-Tech (300653.SZ): The summary report for the calcium-silicon biological ceramic bone repair material has been completed, and it will be submitted for registration in the second half of the year.
On August 8th, Gelon Hui reported that Yantai Zhenghai Bio-Tech (300653.SZ) announced at an investor relations event that as of now, the company's oral pipeline biological repair film is in the stage of registration and compensation, and the calcium-silicon biological ceramic bone repair material has completed the summary report and will be submitted for registration in the second half of the year. These two products are upgrades and iterations of existing products, and the company hopes to further enhance the product power of the membrane powder combination through the layout of new products, thus driving the sales growth of the oral product portfolio.
Yantai Zhenghai Bio-Tech (300653.SZ): The main products are block orders for oral repair films and bone repair materials, and currently neither of the two products are involved in centralized procurement.
Yantai Zhenghai Bio-Tech (300653.SZ) stated in an investor relations activity that the company's block orders for the dental industry include oral restoration membrane and bone repair materials. Currently, these two products are not involved in joint procurement. Joint procurement is affected by various factors and the company will closely monitor the promotion and implementation of relevant joint procurement policies.
Yantai Zhenghai Bio-tech (300653.SZ): The policy of centralized procurement of dental implants has been fully implemented for more than a year, and the overall cost of a single conventional dental implant has been greatly reduced.
Zhenghai Bio-Tech (300653.SZ) stated in an investor relations event on August 8th that as of April 2024, the centralized procurement policy for dental implants has been fully implemented for over a year, leading to a significant decrease in the overall cost of conventional oral implants and a noticeable alleviation of patients' medical burden. With the implementation of the procurement policy, the price gap between public and private oral medical institutions has narrowed and the competition in the private oral industry has become increasingly intense. Although the implant repair materials have not been included in the scope of centralized procurement, they have also been affected by demand fluctuations and downstream cost control in the first half of the year. The company optimized its application for dental-related products in the field of implants.
Yantai Zhenghai Bio-Tech: Summary of Half-Year Report in 2024.
Yantai Zhenghai Bio-Tech: Half-year report for the year 2024.
Little Excitement Around Yantai Zhenghai Biotechnology Co., Ltd.'s (SZSE:300653) Earnings As Shares Take 29% PoundingNo Data
